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Thyrotoxicosis factitia induces
Takotsubo cardiomyopathy
in end-stage renal disease:
a pathogenetic hypothesis
To the Editor: We appreciate the report by Takemoto et al.1
onTakotsubo cardiomyopathy without an identiﬁable cause in a
patient undergoing long-term hemodialysis, which reﬂects the
great diversity of cardiovascular events in end-stage renal
disease patients. Although the etiology of Takotsubo cardio-
myopathy remains unclear in most cases, we would like to bring
to the readers’ attention an unusual cause of this stress
cardiomyopathy. A 31-year-old woman with Chinese herb
nephropathy and on continuous ambulatory peritoneal dialysis
for 16 months developed severe chest pain rapidly after taking
slimming pills containing triiodothyronine (128mg). Transient
left ventricular apical ballooning without evidence of coronary
artery abnormality was documented. In this patient, a burst of
enhanced, excessive sympathetic activity arising from thyrotox-
icosis factitia may have triggered a switch in intracellular signal
trafﬁcking in ventricular cardiomyocytes, from Gs protein to Gi
protein signaling via the b2-adrenergic receptors.
2 This strategy
counteracts the proapoptotic effect of excessive b1-adrenergic
Gs protein pathway activation and seems to act as a
physiological balance to prevent catecholamine-mediated
myocardial damage.3 In our patient, the ventricular function
and apical wall motion returned to normal 2 weeks later.
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Antineutrophil cytoplasmic
autoantibody-associated vasculitis
on chronic dialysis
To the Editor: In a recent issue of Kidney International,
Lionaki et al.1 suggested that in antineutrophil cytoplasmic
autoantibody-associated vasculitis patients on dialysis, immu-
nosuppressants should be restricted to those with active
vasculitis. We quite agree with it, but some data are not
convincing enough to make such a conclusion. First, the
authors reported that in end-stage renal disease (ESRD)
patients, the infection rate was twice as high in patients
who were on immunosuppressants as in those who were
not on immunosuppressants. It is not a pertinent reason
for restricting immunosuppressants in ESRD patients, as
immunosuppressants would deﬁnitely increase the chances
of infection, regardless of ESRD or non-ESRD.2 Instead, the
authors should compare the frequency of infections between
ESRD and non-ESRD patients, both on immunosuppressants,
or demonstrate that in non-ESRD patients, the possibility of
infections being increased by immunosuppressants is much
less than twice. Moreover, other factors contributing to
infections should be adjusted. Second, the authors reported
that among ESRD patients, death rates were similar between
those with and those without active vasculitis. It is improper to
simply compare the ‘percentages’ without considering follow-
up durations. Instead, Cox-regression or, at least, Kaplan–Meier
analysis, should be used. Third, the authors reported that
infections and active vasculitis were the ﬁrst cause of death in
ESRD and non-ESRD patients, respectively. Such comparison
is an unbalance, as the former would mostly have already
received immunosuppressants and would thus be in remission,
while the latter are often in an active state. Instead, the authors
should compare the cause of death between ESRD and non-
ESRD patients, both in active and remission states. In addition,
the unavailability of the causes of death in many patients
makes such comparison unconvincing.
1. Lionaki S, Hogan SL, Jennette CE et al. The clinical course of ANCA small-
vessel vasculitis on chronic dialysis. Kidney Int 2009; 76: 644–651.
2. Chen M, Yu F, Zhang Y et al. Antineutrophil cytoplasmic autoantibody-
associated vasculitis in older patients. Medicine (Baltimore) 2008; 87:
203–209.
Min Chen1 and Ming-Hui Zhao1
1Renal Division, Department of Medicine, Peking University First Hospital,
Institute of Nephrology, Peking University, Key Laboratory of Renal Disease,
Ministry of Health of China, Beijing, China
Correspondence: Min Chen, Renal Division, Department of Medicine, Peking
University First Hospital, Institute of Nephrology, Peking University, Key
Laboratory of Renal Disease, Ministry of Health of China, Beijing 100034,
China. E-mail: leimeng@public3.bta.net.cn
Kidney International (2010) 77, 468; doi:10.1038/ki.2009.492
The Authors Reply: We appreciate the opportunity to
respond to Chen and Zhao1 regarding our analysis of the
clinical course of antineutrophil cytoplasmic autoantibody
small vessel vasculitis2 on chronic dialysis. Drs Chen and
Zhao raise the concern that our results do not support the
statement that immunosuppressive therapy should be geared
only to patients with end-stage renal disease (ESRD) and
l e t te r to the ed i to r http://www.kidney-international.org
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